vimarsana.com

Page 29 - ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Synaffix B V : Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent s Pipeline

Synaffix B V : Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent s Pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Acrivon Therapeutics Launches to Advance Clinical Oncology

Acrivon Therapeutics Launches to Advance Clinical Oncology
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Rob Halford, Sammy Hagar, Lzzy Hale And Sebastian Bach Among Artists Added To Ronnie James Dio Birthday Virtual Fundraiser

Rob Halford, Sammy Hagar, Lzzy Hale And Sebastian Bach Among Artists Added To Ronnie James Dio Birthday Virtual Fundraiser
blabbermouth.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blabbermouth.net Daily Mail and Mail on Sunday newspapers.

Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma

Share this article Share this article SAN FRANCISCO and SUZHOU, China, June 27, 2021 /PRNewswire/  Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab biosimilar injection) as a first-line treatment for people with advanced or unresectable hepatocellular carcinoma (HCC). This is the first regulatory approval of a PD-1 inhibitor-based combination therapy for the first-line treatment for HCC.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.